Merck KGaA Licenses Glenmark Pharmaceuticals' DPPIV Inhibitor for Type 2 Diabetes

Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics by ruth on October 17, 2006

Merck KGaA and Glenmark Pharmaceuticals S.A (Switzerland), a wholly owned subsidiary of India-based Glenmark Pharmaceuticals hve entered into a collaborative agreement to develop Glenmark's DPPIV inhibitor GRC 8200, a treatment for type 2 diabetes, currently under Phase II clinical development. DPPIV inhibitors are a class of drugs that work by inhibiting the activity of the DPP-IV enzyme, thereby stimulating the secretion of higher levels of insulin.

The value of all payments to Glenmark could total up to EUR 190 million, including a EUR 25 million up-front payment and various milestone payments upon successful development and launch of Mono-therapy and combination products based on GRC 8200. Upon commercial launch, Glenmark will supply the active ingredient to Merck and will receive royalties on net sales of the product.

Glenmark retains marketing rights for India while Merck KGaA gains North America, Europe and Japan markets.

Source: Merck

Related Entries:

DPP-4 Inhibitor by Merck: JANUVIA™, Approved by the USFDA fo... - 20 October 2006
DPP-4 Inhibitor JANUVIA® Approved In EU for Type 2 Diabetes - 27 March 2007
Aussie Biotech Co. Offers Safe Diabetes Treatment - 23 April 2007
Interesting Diabetes Links - 12 November 2007

« Van der Woude Gene IRF6 I... | Main | Biofuel Cells From Bacter... »

Permalink: Merck KGaA Licenses Glenmark Pharmaceuticals' DPPIV Inhibitor for Type 2 Diabetes

Tags: diabetes type2+diabetes biotech pharmaceutical insulin glenmark glenmark+pharmaceuticals type+diabet

Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/39469

Addthis

Ask

Blinklist

del.icio.us

Digg

Fark

Facebook

Google

Lycos

Ma.gnolia

Mr Wong

Netscape

Netvousz

Newsvine

StumbleUpon

Slashdot

Tailrank

Technorati

Wink

Yahoo

Vote for Merck KGaA Licenses Glenmark Pharmaceuticals' DPPIV Inhibitor for Type 2 Diabetes:

Currently 9.75/10
1
2
3
4
5
6
7
8
9
10

Rating: 9.75 out of 4 vote(s) cast.

Add your response to Merck KGaA Licenses Glenmark Pharmaceuticals' DPPIV Inhibitor for Type 2 Diabetes:

Name: *

Email: (will never be shown)*

URL:

(* marked fields are required)

Notify me if more comments appear?

Subscribe to The Biotech Weblog newsletter? (Newsletters are sent out weekly).

Remember me

Security Code: *
(Please help us to sort out spam.)

Please enter your comment here: (Sorry, no HTML is allowed - URLs will be made clickable automatically if you add http:// to your URL.)

We welcome your comments, however all comments are moderated. Offensive or off-topic comments will be deleted and not displayed.

Share It

Use the search to look for other interesting posts

Contributors (Last 90 days)

Gloria Gamat (1)
Ruth Schaffer (12)
Creative Weblogging (4)

This site has 1319 entries and is powered by Creative Weblogging since July 2005.

Our Editors recommend

Disclaimer

Some of the contents of this site are protected Creative Weblogging Inc. 2004-2010.

Check out our Sponsored Blogs!

Business Computer Blog (UK)

Testimonials

'Very nice blog layout with great content. Are you interested in Star Trek props that are quickly becoming reality? Then this is the blog for you. Human medical scanners, nano technology and more great technological advancements.' -VirtualLoop Blog of the Week

'I subscribe to your blog and have been enjoying your posts and perspective.'

Other blogs in the same channel in the Creative Weblogging Network: Health & Life Sciences

RSS	See all blog subscribe options
Google	What is RSS?
Yahoo!
Addthis
Bloglines
Newsletter
Twitter	Follow us on Twitter!